JP2017510644A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510644A5
JP2017510644A5 JP2017502935A JP2017502935A JP2017510644A5 JP 2017510644 A5 JP2017510644 A5 JP 2017510644A5 JP 2017502935 A JP2017502935 A JP 2017502935A JP 2017502935 A JP2017502935 A JP 2017502935A JP 2017510644 A5 JP2017510644 A5 JP 2017510644A5
Authority
JP
Japan
Prior art keywords
cycloalkyl
independently
alkyl
membered
membered heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502935A
Other languages
English (en)
Japanese (ja)
Other versions
JP6517319B2 (ja
JP2017510644A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022864 external-priority patent/WO2015148869A1/en
Publication of JP2017510644A publication Critical patent/JP2017510644A/ja
Publication of JP2017510644A5 publication Critical patent/JP2017510644A5/ja
Application granted granted Critical
Publication of JP6517319B2 publication Critical patent/JP6517319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502935A 2014-03-28 2015-03-27 置換されたヘテロアリール化合物および使用方法 Active JP6517319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971552P 2014-03-28 2014-03-28
US61/971,552 2014-03-28
PCT/US2015/022864 WO2015148869A1 (en) 2014-03-28 2015-03-27 Substituted heteroaryl compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2017510644A JP2017510644A (ja) 2017-04-13
JP2017510644A5 true JP2017510644A5 (cg-RX-API-DMAC7.html) 2018-03-22
JP6517319B2 JP6517319B2 (ja) 2019-05-22

Family

ID=54189377

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017502933A Active JP6517318B2 (ja) 2014-03-28 2015-03-27 置換されたヘテロアリール化合物および使用方法
JP2017502934A Active JP6538148B2 (ja) 2014-03-28 2015-03-27 置換されたヘテロアリール化合物および使用方法
JP2017502935A Active JP6517319B2 (ja) 2014-03-28 2015-03-27 置換されたヘテロアリール化合物および使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017502933A Active JP6517318B2 (ja) 2014-03-28 2015-03-27 置換されたヘテロアリール化合物および使用方法
JP2017502934A Active JP6538148B2 (ja) 2014-03-28 2015-03-27 置換されたヘテロアリール化合物および使用方法

Country Status (7)

Country Link
US (3) US9403801B2 (cg-RX-API-DMAC7.html)
EP (5) EP3122729A4 (cg-RX-API-DMAC7.html)
JP (3) JP6517318B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015235880B2 (cg-RX-API-DMAC7.html)
CA (1) CA2943979A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016012574A (cg-RX-API-DMAC7.html)
WO (3) WO2015148867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9403801B2 (en) * 2014-03-28 2016-08-02 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US11517026B2 (en) 2014-09-11 2022-12-06 Koninklijke Philips N.V. Method for controlling a process of roasting coffee beans and device for use in a process for roasting coffee beans
CN106478651B (zh) * 2015-08-31 2019-07-09 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
EP3347097B1 (en) * 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US20170081338A1 (en) * 2015-09-17 2017-03-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
JP6453794B2 (ja) * 2016-03-07 2019-01-16 Ckd株式会社 検査装置、ブリスタ包装機、ｐｔｐシートの製造方法および錠剤
SG10201912632YA (en) 2016-06-16 2020-02-27 Denali Therapeutics Inc Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
EP3552247B1 (en) 2016-12-09 2020-04-29 Koninklijke Philips N.V. Actuator device and method
WO2018169700A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EP3710006A4 (en) * 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
CN110833553A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗Arthus反应的用途
WO2021043850A1 (en) * 2019-09-05 2021-03-11 Universität Bern Tricyclic janus kinase (jak) inhibitors and their use in the treatment of autoimmune diseases
CN110862376A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物
CA3161667A1 (en) * 2019-12-16 2021-06-24 Pil Ho Kim Novel pyrimidine derivative and use thereof
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4644394A2 (en) 2020-02-18 2025-11-05 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TW202229242A (zh) * 2020-09-10 2022-08-01 大陸商四川海思科製藥有限公司 一種碳環醯胺衍生物及其在醫藥上的應用
CN115087641B (zh) * 2021-01-11 2024-06-18 广州力鑫生物科技有限公司 2-氨基嘧啶类化合物及其药物组合物和应用
KR20230170745A (ko) 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN117064888A (zh) * 2023-09-26 2023-11-17 中国科学院水生生物研究所 氯喹或其药学上可接受的盐在制备预防生产非整倍体配子的药物中的应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE191470T1 (de) 1994-06-15 2000-04-15 Wellcome Found Enzymhemmer
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag, Basel Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ATE213730T1 (de) 1996-04-12 2002-03-15 Warner Lambert Co Umkehrbare inhibitoren von tyrosin kinasen
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
ATE247724T1 (de) 1996-09-06 2003-09-15 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PT1367057E (pt) 1996-11-18 2008-12-04 Biotechnolog Forschung Gmbh Epotilonas e e f
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
AU4501800A (en) 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
BR0114323A (pt) 2000-09-29 2003-07-01 Glaxo Group Ltd Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto
DE60140201D1 (en) 2000-11-07 2009-11-26 Novartis Ag Indolylmaleimidderivative als proteinkinase-c-inhibitoren
PT1355905E (pt) * 2000-12-21 2007-05-31 Vertex Pharma Compostos de pirazole úteis como inibidores de proteínaquinase
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
DE60309829T2 (de) 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
UA80120C2 (en) 2002-03-26 2007-08-27 Boehringer Ingelheim Pharma Glucocorticoid mimetics, pharmaceutical composition based thereon
US7268152B2 (en) 2002-03-26 2007-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2491994C (en) 2002-07-08 2013-11-05 Pfizer Products Inc. Modulators of the glucocorticoid receptor
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
CN101044135B (zh) 2004-10-19 2011-11-23 霍夫曼-拉罗奇有限公司 喹啉衍生物
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
BRPI0814432A2 (pt) 2007-07-17 2017-05-09 Rigel Pharmaceuticals Inc pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
WO2009080638A2 (en) * 2007-12-20 2009-07-02 Cellzome Limited Sulfamides as zap-70 inhibitors
CA2960692C (en) * 2008-04-16 2019-09-24 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
WO2010083241A2 (en) 2009-01-14 2010-07-22 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
EP2389373B1 (en) 2009-01-21 2017-05-17 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
KR20110132607A (ko) 2009-03-24 2011-12-08 엠에스디 가부시키가이샤 오로라 ａ 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
MX2011013325A (es) * 2009-06-10 2012-04-30 Abbott Lab 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
CA2780759A1 (en) 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8710223B2 (en) 2010-07-21 2014-04-29 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
WO2012059932A1 (en) * 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
AU2011328139A1 (en) * 2010-11-10 2013-04-04 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as LRRK2 modulators
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
JP6141334B2 (ja) * 2012-02-17 2017-06-07 アッヴィ・インコーポレイテッド ヒト呼吸器多核体ウイルス（ｒｓｖ）の阻害剤として有用なジアミノピリミジン
EP2833889B1 (en) 2012-04-04 2017-11-01 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
BR112014027117B1 (pt) * 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
CN104583195B (zh) 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
EP2903617B1 (en) 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
US9169249B2 (en) 2013-03-14 2015-10-27 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
CN104262328B (zh) 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
US9403801B2 (en) * 2014-03-28 2016-08-02 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use

Similar Documents

Publication Publication Date Title
JP2017510644A5 (cg-RX-API-DMAC7.html)
JP2017510642A5 (cg-RX-API-DMAC7.html)
JP2017510643A5 (cg-RX-API-DMAC7.html)
JP2017531000A5 (cg-RX-API-DMAC7.html)
JP2020537657A5 (cg-RX-API-DMAC7.html)
JP2014037426A5 (cg-RX-API-DMAC7.html)
ES2438998T3 (es) Terapias combinadas que comprenden un inhibidor de quinaxolina de PI3K alfa para utilizar en el tratamiento del cáncer
JP2019510787A5 (cg-RX-API-DMAC7.html)
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
JP2020521741A5 (cg-RX-API-DMAC7.html)
JP2020528889A5 (cg-RX-API-DMAC7.html)
JP2016530283A5 (cg-RX-API-DMAC7.html)
JP2018533611A5 (cg-RX-API-DMAC7.html)
JP2017533968A5 (cg-RX-API-DMAC7.html)
JP2019518071A5 (cg-RX-API-DMAC7.html)
JP2015514056A5 (cg-RX-API-DMAC7.html)
EP3541813A1 (en) Heterocyclic amides as kinase inhibitors
JP2013544261A5 (cg-RX-API-DMAC7.html)
JP2017505808A5 (cg-RX-API-DMAC7.html)
JP2010540602A5 (cg-RX-API-DMAC7.html)
JP2017537948A5 (cg-RX-API-DMAC7.html)
JP2014509647A5 (cg-RX-API-DMAC7.html)
JP2017512786A5 (cg-RX-API-DMAC7.html)
JP2015510894A5 (cg-RX-API-DMAC7.html)
JP2018501315A5 (cg-RX-API-DMAC7.html)